<DOC>
	<DOCNO>NCT01128738</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority single treatment GSK1358820 ( hereinafter , refer BOTOX® ) placebo term efficacy treatment BOTOX® 50 U axilla ( 100 U total patient ) intradermal injection base gravimetric assessment ( measurement spontaneous axillary sweat production ) axillary hyperhidrosis .</brief_summary>
	<brief_title>GSK1358820 ( Botulinum Toxin A ) PhIII DB &amp; OL Study Patients With Axillary Hyperhidrosis</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>&lt; At start screen phase ( Visit 1 ) &gt; At least 50 mg spontaneous rest axillary sweat production axilla measure gravimetrically room temperature/humidity ( 20 25.6°C/2080 % ) period 5 minute . ( Patients rest least 30 minute physical exercise include walk . ) Patients primary axillary hyperhidrosis whose excessive sweating axilla interfere daily life activity whose Hyperhidrosis Disease Severity Scale ( HDSS ) score 3 4 . Age 20 75 year time inform consent . Both gender eligible enrol study . For men , practice contraception study period eligible . Women childbearing potential may enrol negative pregnancy test screen period treatment . Women childbearing potential must agree use one follow reliable contraceptive measure throughout study period : * : Abstinence , oral contraceptive , progesterone injection , levonorgestrel implant , estrogen ring , transdermal contraceptive , intrauterine device , vasectomized partner , doublebarrier contraception ( condom diaphragm spermicidal jelly/film ) . QTc &lt; 450 msec , QTc &lt; 480 msec patient bundle branch block . ( QTc determine one beat echocardiogram ( ECG ) determine average consecutive three beat . ) Willing able provide write informed consent . &lt; At start treatment phase ( Visit 2 ) &gt; At least 50 mg spontaneous rest axillary sweat production axilla measure gravimetrically room temperature/humidity ( 20 25.6°C/2080 % ) period 5 minute . ( Patients rest least 30 minute physical exercise include walk . ) Patients primary axillary hyperhidrosis whose excessive sweating axilla interfere daily life activity whose HDSS score 3 4 . Asparate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; 2 x upper limit normal ( ULN ) , Alkaline phosphatase ( ALP ) bilirubin &lt; = 1.5 x ULN Visit 1 ( Free bilirubin &gt; = 1.5 × ULN directly lead study discontinuation bilirubin fraction test result direct bilirubin &lt; 35 % available . ) &lt; At start screen phase ( Visit 1 ) &gt; Any systemic neuromuscular junction disorder ( e.g. , myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis ) . Previous botulinum toxin treatment . Expected use botulinum toxin treatment disease study period . Known allergy component investigational product iodine . Secondary hyperhidrosis , example , hyperhidrosis secondary underlying disease include hyperthyroidism , lymphoma malaria . Previous surgical treatment hyperhidrosis include sympathectomy , surgical debulking sweat gland , subcutaneous tissue curettage ultrasonic surgery . Concurrent use antibiotic may interfere neuromuscular junction function , example , aminoglycoside antibiotic ( e.g. , gentamicin sulfate , fradiomycin sulfate ) , polypeptide antibiotic ( e.g. , polymixin B sulfate ) , tetracycline antibiotic , lincomycin antibiotic , except contain topical antimicrobial . Concurrent use muscle relaxant ( e.g. , tubocurarin chloride hydrochloride hydrate , dantrolene sodium hydrate ) drug may muscle relaxant action ( e.g . spectinomycin hydrochloride hydrate , antispasmogenics include baclofen , benzodiazepine benzodiazepinelike drug , benzamides ) . Chronic respiratory disorder . Serious muscle weakness atrophy . Angle closure glaucoma precipitation ( narrow angle ) . Dermal disorder include infection anticipate injection sit either axilla . Subject serious physical symptom ( ) ( i.e. , cardiac / hepatic / renal / hematopoietic disorder ) . The index seriousness Grade 3 `` criterion classification seriousness adverse drug reaction pharmaceutical product , etc . : Appendix 3 '' ( Pharmaceutical Affairs bureau / Pharmaceutical Chemical Safety Division ( PAB / PSD ) Notification No.80 1992 ) . Anticipated need surgery hospitalization study period . Women pregnant , lactate , possibly pregnant planning pregnancy study period . Participation another clinical study within 6 month study entry plan participation another clinical study entry study . Psychiatry disorder cognitive disorder may affect patient 's ability give inform consent follow specify study procedure . History alcohol drug abuse . Any condition situation , investigator 's subinvestigator 's opinion , may interfere patient 's participation study . &lt; At start treatment phase ( Visit 2 ) &gt; Use cholinomimetics , anticholinergic , antiperspirant contain aluminum chloride deodorant , oral herbal medicine treatment topical treatment hyperhidrosis within 7 day prior study treatment.. Underarm hair remove within 12 hour prior study treatment remove sufficiently . Any condition situation , investigator 's subinvestigator 's opinion , may interfere patient 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Neuromuscular Agents</keyword>
	<keyword>Botulinum Toxin Type A</keyword>
	<keyword>Sweating</keyword>
	<keyword>Sweat Gland Disease</keyword>
	<keyword>Axillary Hyperhidrosis</keyword>
	<keyword>Skin Disease</keyword>
</DOC>